8 research outputs found
Finishing the euchromatic sequence of the human genome
The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead
Recommended from our members
MadeenErinEMTHumanInVivo.pdf
Dibenzo(def,p)chrysene (DBC), (also known as dibenzo[a,l]pyrene), is a high molecular weight
polycyclic aromatic hydrocarbon (PAH) found in the environment, including food, produced by
the incomplete combustion of hydrocarbons. DBC, classified by IARC as a 2A probable human
carcinogen, has a relative potency factor (RPF) in animal cancer models 30-fold higher than
benzo[a]pyrene. No data are available describing disposition of high molecular weight (>4 rings)
PAHs in humans to compare to animal studies. Pharmacokinetics of DBC was determined in 3
female and 6 male human volunteers following oral micro-dosing (29 ng, 5 nCi) of [14C]-DBC.
This study was made possible with highly sensitive accelerator mass spectrometry (AMS),
capable of detecting [14C]-DBC equivalents in plasma and urine following a dose considered of
de minimus risk to human health. Plasma and urine were collected over 72 h. The plasma Cmax
was 68.8 ± 44.3 fg*mL-1 with a Tmax of 2.25 ± 1.04 h. Elimination occurred in two distinct
phases; a rapid (α)-phase, with a T1/2 of 5.8 ± 3.4 h and apparent elimination rate constant (Kel)
of 0.17 ± 0.12 fg*h-1 followed by a slower (β)-phase, with a T1/2 of 41.3 ± 29.8 h and apparent
Kel of 0.03 ± 0.02 fg*h-1. In spite of the high degree of hydrophobicity (log Kow of 7.4), DBC was
eliminated rapidly in humans, as are most PAHs in animals, compared to other hydrophobic
persistent organic pollutants such as, DDT, PCBs and TCDD. Preliminary examination utilizing
a new UHPLC-AMS interface, suggests the presence of polar metabolites in plasma as early as
45 min following dosing. This is the first in vivo dataset describing pharmacokinetics in humans
of a high molecular weight PAH and should be a valuable addition to risk assessment paradigms.To the best of our knowledge, one or more authors of this paper were federal employees when contributing to this work. This is the publisher’s final pdf. The published article is copyrighted by the American Chemical Society and can be found at: https://doi.org/10.1021/tx5003996Keywords: pharmacokinetics, dibenzo(def\, p)chrysene, accelerator mass spectrometry, polycyclic aromatic hydrocarbon, human micro-dosin
Recommended from our members
MadeenErinEMTHumanInVivo.pdf
Dibenzo(def,p)chrysene (DBC), (also known as dibenzo[a,l]pyrene), is a high molecular weight
polycyclic aromatic hydrocarbon (PAH) found in the environment, including food, produced by
the incomplete combustion of hydrocarbons. DBC, classified by IARC as a 2A probable human
carcinogen, has a relative potency factor (RPF) in animal cancer models 30-fold higher than
benzo[a]pyrene. No data are available describing disposition of high molecular weight (>4 rings)
PAHs in humans to compare to animal studies. Pharmacokinetics of DBC was determined in 3
female and 6 male human volunteers following oral micro-dosing (29 ng, 5 nCi) of [14C]-DBC.
This study was made possible with highly sensitive accelerator mass spectrometry (AMS),
capable of detecting [14C]-DBC equivalents in plasma and urine following a dose considered of
de minimus risk to human health. Plasma and urine were collected over 72 h. The plasma Cmax
was 68.8 ± 44.3 fg*mL-1 with a Tmax of 2.25 ± 1.04 h. Elimination occurred in two distinct
phases; a rapid (α)-phase, with a T1/2 of 5.8 ± 3.4 h and apparent elimination rate constant (Kel)
of 0.17 ± 0.12 fg*h-1 followed by a slower (β)-phase, with a T1/2 of 41.3 ± 29.8 h and apparent
Kel of 0.03 ± 0.02 fg*h-1. In spite of the high degree of hydrophobicity (log Kow of 7.4), DBC was
eliminated rapidly in humans, as are most PAHs in animals, compared to other hydrophobic
persistent organic pollutants such as, DDT, PCBs and TCDD. Preliminary examination utilizing
a new UHPLC-AMS interface, suggests the presence of polar metabolites in plasma as early as
45 min following dosing. This is the first in vivo dataset describing pharmacokinetics in humans
of a high molecular weight PAH and should be a valuable addition to risk assessment paradigms.To the best of our knowledge, one or more authors of this paper were federal employees when contributing to this work. This is the publisher’s final pdf. The published article is copyrighted by the American Chemical Society and can be found at: https://doi.org/10.1021/tx5003996Keywords: accelerator mass spectrometry, human micro-dosing, polycyclic aromatic hydrocarbon, pharmacokinetics, dibenzo(def\, p)chryseneKeywords: accelerator mass spectrometry, human micro-dosing, polycyclic aromatic hydrocarbon, pharmacokinetics, dibenzo(def\, p)chrysen
The metagenome of the marine anammox bacterium ‘Candidatus Scalindua profunda’ illustrates the versatility of this globally important nitrogen cycle bacterium
Anaerobic ammonium-oxidizing (anammox) bacteria are responsible for a significant portion of the loss of fixed nitrogen from the oceans, making them important players in the global nitrogen cycle. To date, marine anammox bacteria found in marine water columns and sediments worldwide belong almost exclusively to the 'Candidatus Scalindua' species, but the molecular basis of their metabolism and competitive fitness is presently unknown. We applied community sequencing of a marine anammox enrichment culture dominated by 'Candidatus Scalindua profunda' to construct a genome assembly, which was subsequently used to analyse the most abundant gene transcripts and proteins. In the S. profunda assembly, 4756 genes were annotated, and only about half of them showed the highest identity to the only other anammox bacterium of which a metagenome assembly had been constructed so far, the freshwater 'Candidatus Kuenenia stuttgartiensis'. In total, 2016 genes of S. profunda could not be matched to the K. stuttgartiensis metagenome assembly at all, and a similar number of genes in K. stuttgartiensis could not be found in S. profunda. Most of these genes did not have a known function but 98 expressed genes could be attributed to oligopeptide transport, amino acid metabolism, use of organic acids and electron transport. On the basis of the S. profunda metagenome, and environmental metagenome data, we observed pronounced differences in the gene organization and expression of important anammox enzymes, such as hydrazine synthase (HzsAB), nitrite reductase (NirS) and inorganic nitrogen transport proteins. Adaptations of Scalindua to the substrate limitation of the ocean may include highly expressed ammonium, nitrite and oligopeptide transport systems and pathways for the transport, oxidation, and assimilation of small organic compounds that may allow a more versatile lifestyle contributing to the competitive fitness of Scalindua in the marine realm